Adenosine A_2A receptor agonists with potent antiplatelet activity

References

• Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011;25:155–167.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Several platelet receptors and their ligands are involved in platelet- dependent thrombus formation. Thromb Res 2011;132:313.
   Web of Science ®Google Scholar
• Gurbel PA, Jeong YH, Navarese EP, Tantry, U.S. Platelet-Mediated Thrombosis: From Bench to Bedside. Circ Res 2016;118:1380–1391.
   PubMed Web of Science ®Google Scholar
• Mbewu A, Mbanya, JC. Cardiovascular disease. In: Jamison DT, Feachem RG, Makgoba MW, et al., editors. Disease and mortality in sub-Saharan Africa. Washington, DC: World Bank; 2006. pp. 305–328.
   Google Scholar
• Harrington RA, Hodgson PK, Larsen RL. Cardiology patient page. Antiplatelet therapy. Circulation 2003;108:e45–e47.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Park Y, Angiolillo DJ. Novel antiplatelet agents: The current state and what is coming down the pike. Prog Cardiovasc Dis 2015;58:267–277.
   PubMed Web of Science ®Google Scholar
• Ellis KJ, Stouffer GA, McLeod, HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009;10:1799–1817.
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici, P, Gensini GF., Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215–1223.
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Homs S, Berdejo J, Roura G, Gomez-Lara J, Romaguera R, Teruel L, Sanchez-Elvira G, Marcano AL, Gomez-Hospital JA. et al. Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thromb Haemost 2013;110:110–117.
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato, E. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010;3:35–40.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606–617.
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J. Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:199S–233S.
   Google Scholar
• Tantry US, Etherington A, Bliden KP, Gurbel PA. Antiplatelet therapy: Current strategies and future trends. Future Cardiol 2006;2:343–366.
   PubMedGoogle Scholar
• Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010;56:1683–1692.
   PubMed Web of Science ®Google Scholar
• Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV, Jr, Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen D.J. Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: Results from the CRUSADE Initiative. J Am Coll Cardiol 2007;49:1790–1797.
   PubMed Web of Science ®Google Scholar
• Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004;35:2362–2367.
   PubMed Web of Science ®Google Scholar
• de Lera Ruiz M, Lim YH, Zheng J. Adenosine A2A receptor as a drug discovery target. J Med Chem 2014;57:3623–3650.
   PubMed Web of Science ®Google Scholar
• Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, Tate CG. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 2011;474:521–525.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Caballero J, AlarcÃ3n M, Rojas A, Palomo I.n. Chlorogenic acid inhibits human platelet activation and thrombus formation. PLoS One 2014;9:e90699.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Badimon L, Caballero J, Padro T, Vilahur G, Alarcon M, Perez P, Palomo I. Protective mechanisms of adenosine 5’-monophosphate in platelet activation and thrombus formation. Thromb Haemost 2014;111:491–507.
   PubMed Web of Science ®Google Scholar
• El-Tayeb A, Iqbal J, Behrenswerth A, Romio M, Schneider M, Zimmermann H, Schrader J, Muller CE. Nucleoside-5’-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5’-nucleotidase. J Med Chem 2009;52:7669–7677.
   PubMed Web of Science ®Google Scholar
• Volpini R, Costanzi S, Lambertucci C, Portino F, Taffi S, Vittori S, Zablocki J, Klotz KN, Cristalli G. Adenosine receptor agonists: synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives. ARKIVOC;5:301–311.
   Google Scholar
• Alnouri MW, Jepards S, Casari A, Schiedel AC, Hinz S, Muller CE. Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. Purinergic Signal 2015;11:389–407.
   PubMed Web of Science ®Google Scholar
• Sauer R, Maurinsh J, Reith U, Fulle F, Klotz KN, Muller CE. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem 2000;43:440–448.
   PubMed Web of Science ®Google Scholar
• Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol 2006;70:1380–1389.
   PubMed Web of Science ®Google Scholar
• Abagyan R, Totrov M, Kuznetsov D. ICM: A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 1994;15:488–506.
   Web of Science ®Google Scholar
• Alzate-Morales JH, Vergara-Jaque A, Caballero J. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: An unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site. J Chem Inf Model 2010;50:1101–1112.
   PubMed Web of Science ®Google Scholar
• Lebon G, Edwards PC., Leslie AG, Tate CG. Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. Mol Pharmacol 2015;87:907–915.
   PubMed Web of Science ®Google Scholar
• An J, Totrov M, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 2005;4:752–761.
   PubMed Web of Science ®Google Scholar
• Fotheringham AS, Brunsdon C. Local forms of spatial analysis. Geographical Analysis 1999;31:340–358.
   Web of Science ®Google Scholar
• Amisten S, Braun OO, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008;122:47–57.
   PubMed Web of Science ®Google Scholar
• De Filippo E, Namasivayam V, Zappe L, El-Tayeb A, Schiedel AC, Muller CE. Role of extracellular cysteine residues in the adenosine A2A receptor. Purinergic Signal 2016;12:313–329.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Pereira J, Mezzano D, Alarcon M, Caballero J, Palomo I. Inhibition of platelet activation and thrombus formation by adenosine and inosine: Studies on their relative contribution and molecular modeling. PLoS One 2014;9:e112741.
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938–949.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227–1234.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Palomo I. Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk. Thromb Res 2014;134:221–226.
   PubMed Web of Science ®Google Scholar
• Siddique A, Butt M, Shantsila E, Lip GY. New antiplatelet drugs: Beyond aspirin and clopidogrel. Int J Clin Pract 2009;63:776–789.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: New pharmacological agents and changing paradigms. J Thromb Haemost 2013;11 Suppl 1:316–329.
   PubMed Web of Science ®Google Scholar
• Gachet C. Antiplatelet drugs: Which targets for which treatments? J Thromb Haemost 2015;13 Suppl 1:S313–S322.
   PubMed Web of Science ®Google Scholar
• Hechler B, Freund M, Alame G, Leguay C, Gaertner S, Cazenave, JP, Petitou M, Gachet C. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds. J Pharmacol Exp Ther 2011;338:412–420.
   PubMed Web of Science ®Google Scholar
• Johnston-Cox HA, Koupenova M, Ravid K. A2 adenosine receptors and vascular pathologies. Arterioscler Thromb Vasc Biol 2012;32:870–878.
   PubMed Web of Science ®Google Scholar
• Fredholm BBAPIJ., Jacobson KA, Linden J, Muller CE. international union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 2011;63:1–34.
   Google Scholar
• Rodriguez D, Pineiro A, Gutierrez-de-Teran H. Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. Biochemistry 2011;50:4194–4208.
   PubMed Web of Science ®Google Scholar
• Guo D, Mulder-Krieger TAPIJ, Heitman LH. Functional efficacy of adenosine A(2)A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 2012;166:1846–1859.
   PubMed Web of Science ®Google Scholar
• Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane, JR, Ijzerman AP, Stevens, RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322:1211–1217.
   PubMed Web of Science ®Google Scholar
• Krupnick, JG, Benovic, JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998;38:289–319.
   PubMed Web of Science ®Google Scholar
• Mundell S, Kelly E. Adenosine receptor desensitization and trafficking. Biochim Biophys Acta 2011;1808:1319–1328.
   PubMed Web of Science ®Google Scholar
• Klaasse EC, Ijzerman AP, de Grip WJ, Beukers MW Internalization and desensitization of adenosine receptors. Purinergic Signal 2008;4:21–37.
   PubMed Web of Science ®Google Scholar
• Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. Adenosine receptors: Expression, function and regulation. Int J Mol Sci 2014;15:2024–2052.
   PubMed Web of Science ®Google Scholar
• Hein TW, Belardinelli L, Kuo L. Adenosine A(2A) receptors mediate coronary microvascular dilation to adenosine: Role of nitric oxide and ATP-sensitive potassium channels. J Pharmacol Exp Ther 1999;291:655–664.
   PubMed Web of Science ®Google Scholar
• Shen FM, Su DF. The effect of adenosine on blood pressure variability in sinoaortic denervated rats is mediated by adenosine A2a-Receptor. J Cardiovasc Pharmacol 2000;36:681–686.
   PubMed Web of Science ®Google Scholar
• El-Tayeb A, Michael S, Abdelrahman A, Behrenswerth A, Gollos S, Nieber K, Muller CE. Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists. ACS Med Chem Lett 2011;2:890–895.
   PubMed Web of Science ®Google Scholar